Welcome!

News Feed Item

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 7
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 31
Apr 20, 2011: Advancell Initiates Clinical Phase IIb Study Of ATH008 In Hand-foot Syndrome 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
F. Hoffmann-La Roche Ltd. 32
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 32
Merck & Co., Inc. 33
Clinical Trial Overview of Merck & Co., Inc. 33
Cahaba Pharmaceuticals 34
Clinical Trial Overview of Cahaba Pharmaceuticals 34
Advancell 35
Clinical Trial Overview of Advancell 35
Clinical Trial Overview of Top Institutes / Government 36
Northwestern University 36
Clinical Trial Overview of Northwestern University 36
Cambridge University Hospitals NHS Foundation Trust 37
Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust 37
Asan Medical Center 38
Clinical Trial Overview of Asan Medical Center 38
North Central Cancer Treatment Group 39
Clinical Trial Overview of North Central Cancer Treatment Group 39
Sun Yat-sen University 40
Clinical Trial Overview of Sun Yat-sen University 40
Case Comprehensive Cancer Center 41
Clinical Trial Overview of Case Comprehensive Cancer Center 41
Duke University 42
Clinical Trial Overview of Duke University 42
West Virginia University 43
Clinical Trial Overview of West Virginia University 43
University of California, San Francisco 44
Clinical Trial Overview of University of California, San Francisco 44
University of Wisconsin Madison 45
Clinical Trial Overview of University of Wisconsin Madison 45
Five Key Clinical Profiles 46
Appendix 60
Abbreviations 60
Definitions 60
Research Methodology 61
Secondary Research 61
About GlobalData 62
Contact Us 62
Disclaimer 62
Source 63

List of Tables

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 32
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 33
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cahaba Pharmaceuticals, 2014* 34
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Advancell, 2014* 35
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 36
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014* 37
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 38
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 39
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 40
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 41
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 42
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by West Virginia University, 2014* 43
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 44
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 45

List of Figures
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 61

To order this report: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and atten...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to m...
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...